These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6388930)

  • 21. Mutagenicity, carcinogenicity and teratogenicity of antimony compounds.
    Léonard A; Gerber GB
    Mutat Res; 1996 Oct; 366(1):1-8. PubMed ID: 8921983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dying to live.
    Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
    [No Abstract]   [Full Text] [Related]  

  • 23. 45 years later...where do we stand?
    Benegbi M
    Can J Clin Pharmacol; 2007; 14(1):e37-9. PubMed ID: 17213509
    [No Abstract]   [Full Text] [Related]  

  • 24. Laboratory tests during clinical trials.
    Scand J Clin Lab Invest Suppl; 1989; 195():16-8. PubMed ID: 2799277
    [No Abstract]   [Full Text] [Related]  

  • 25. Mutagenicity, carcinogenicity and teratogenicity of aluminium.
    Léonard A; Gerber GB
    Mutat Res; 1988 Nov; 196(3):247-57. PubMed ID: 3059176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research and development of new medicines.
    Ankier SI; Warrington SJ
    J Int Med Res; 1989; 17(5):407-16. PubMed ID: 2680676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research in the field of clinical pharmacology in the USSR].
    Lakin KM; Makarov VA; Novikova NV
    Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Teratogenic and mutagenic risks of radiotherapy: when and how to prescribe contraception].
    Marty M; Mignot L; Gisselbrecht G; Morvan F; Gorins A; Boiron M
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):181-6. PubMed ID: 12280202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer risks of medical treatment. Part I: Monitoring for drug safety and efficacy.
    Schottenfeld D
    Clin Bull; 1980; 10(4):150-7. PubMed ID: 7011593
    [No Abstract]   [Full Text] [Related]  

  • 30. [Evaluation of the therapeutic risk].
    Zapata A; Costa J; Salvà P
    Med Clin (Barc); 1996 Mar; 106(10):383-6. PubMed ID: 8637279
    [No Abstract]   [Full Text] [Related]  

  • 31. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [General problems in the study of the mutagenic properties of drugs].
    Durnev AD; Volgareva GM; Seredenin SB
    Eksp Klin Farmakol; 1998; 61(2):4-12. PubMed ID: 9621164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recommendations for improving the predictive value of phase I to III data concerning the clinical and biological tolerance of a new drug].
    Auriche M
    Therapie; 1987; 42(4):335-7. PubMed ID: 3686466
    [No Abstract]   [Full Text] [Related]  

  • 34. [List of factors with mutagenic and teratogenic effects on the fetus (drugs, chemical substances, ionizing radiation)].
    Kotásek A; Vanĕcek J; Stark O; Cervenka J; Svihovec V; Srám J
    Cesk Gynekol; 1983 Jul; 48(6):453-6. PubMed ID: 6616686
    [No Abstract]   [Full Text] [Related]  

  • 35. [Projection and evaluation of clinical toxicity of new drugs].
    Adami E; Fresia P
    Arch Ital Sci Farmacol; 1964 Apr; 14(2):200-13. PubMed ID: 5320792
    [No Abstract]   [Full Text] [Related]  

  • 36. The disfranchisement of fertile women in clinical trials: the legal ramifications of and solutions for rectifying the knowledge gap.
    Bowles LE
    Vanderbilt Law Rev; 1992 May; 45(4):877-920. PubMed ID: 16047448
    [No Abstract]   [Full Text] [Related]  

  • 37. Chloroform: a review of its metabolism, teratogenic, mutagenic, and carcinogenic potential.
    Davidson IW; Sumner DD; Parker JC
    Drug Chem Toxicol; 1982; 5(1):1-87. PubMed ID: 6807664
    [No Abstract]   [Full Text] [Related]  

  • 38. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
    Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationships between experimental toxicity and clinical toxicity].
    Beccari E
    Arch Ital Sci Farmacol; 1964 Apr; 14(2):186-99. PubMed ID: 5843459
    [No Abstract]   [Full Text] [Related]  

  • 40. [Toward the study of the problem of the carcinogenic activity of medicinal preparations].
    Naialkov NP; Shabad LM
    Vopr Onkol; 1966; 12(10):3-8. PubMed ID: 6002159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.